Clinical Trials Logo

Filter by:
NCT ID: NCT02916615 Completed - Hypertension Clinical Trials

Effects of Nitrate in Vegetables on Blood Pressure in Subjects With Prehypertension

DINO
Start date: January 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of different vegetables on cardiovascular function in subjects with moderately increased blood pressure. Specifically we are comparing the effects of vegetables with a high natural content of inorganic nitrate with those of vegetables with a low nitrate content.

NCT ID: NCT02916589 Completed - Inflammation Clinical Trials

Nutrition, Oral Health and Type 2 Diabetes

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Obesity continues to pose major public health challenges worldwide with cardiovascular damage, hypertension and diabetes as possible subsequent conditions. The obese are at risk for mortality and morbidity as they suffer from a high level of immune sensitivity with consequences related to damage to the circulation and microvasculature. The immune process itself is modulated by cytokines, which are small proteins which can modulate the spectrum of the inflammatory process. These proteins may act as biomarkers in the mouth. Diabetes is also a consequence of sustained obesity and this condition can strongly influence immune status. Diabetes is characterized by the failure to produce the hormone insulin or a loss of sensitivity to insulin. Without insulin high blood glucose results in the release of a series of pro-inflammatory factors, which lead to pathological processes in several organs leading to high mortality and morbidity. Periodontitis, a common complication of diabetes, is an inflammatory condition of the soft tissue of the periodontium, causing alveolar bone loss. The accessibility of the oral cavity facilitates the study of early inflammatory processes. Changes in diet may reduce inflammation, controlling gingival inflammation as well as clinical treatment. Since 2004 Igelösa Life Science AB has developed a modified Nordic diet based on evidence, primarily from the Japanese island of Okinawa, where the world's oldest and most healthy people live. In this study we will investigate the association between Igelösa dietary intake and measurements of inflammation in 30 overweight individuals with or without other systemic diseases.

NCT ID: NCT02915705 Completed - Clinical trials for X-Linked Hypophosphatemia

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

Start date: September 8, 2016
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).

NCT ID: NCT02915159 Completed - Sjogrens Disease Clinical Trials

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

Start date: December 6, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.

NCT ID: NCT02914873 Recruiting - Prostate Cancer Clinical Trials

SPCG17: Prostate Cancer Active Surveillance Trigger Trial

PCASTT
Start date: October 2016
Phase: N/A
Study type: Interventional

A large proportion of men with prostate cancer are overdiagnosed and overtreated mainly due to PSA testing. Active surveillance (AS) aims to reduce these harms by recommending curative treatment only when and if signs of tumor progression occur. There are however a number of uncertainties in AS, the most important being when to initiate treatment. The investigators are therefore starting a large randomized multicenter trial testing the safety of a standardized active surveillance protocol with specified triggers for repeat biopsies and initiation of curative treatment. The standardized protocol is compared with current practice for active surveillance. The primary aim of the study is to reduce overtreatment and subsequent side effects, without increasing the risk of disease progression or prostate cancer mortality.

NCT ID: NCT02914756 Completed - Sepsis Clinical Trials

HMGB1 in ICU-survivors

Start date: May 2014
Phase:
Study type: Observational

Is HMGB1 (High Mobility Group Box 1) elevated in sepsis patients for weeks after recovery from severe sepsis/septic shock, similar to what has been observed in mice? Do patients recovering from severe sepsis/septic shock suffer from cognitive impairment and is such impairment associated with prolonged HMGB1 levels in plasma? Is there a difference from patients recovering from critical illness without prior sepsis?

NCT ID: NCT02914600 Terminated - Crohn's Disease Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

DIVERSITYLTE
Start date: March 17, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).

NCT ID: NCT02914561 Completed - Crohn's Disease Clinical Trials

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

DIVERSITY1
Start date: October 31, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Study GS-US-419-3896).

NCT ID: NCT02914535 Active, not recruiting - Ulcerative Colitis Clinical Trials

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

SELECTIONLTE
Start date: February 23, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).

NCT ID: NCT02914522 Completed - Ulcerative Colitis Clinical Trials

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

SELECTION
Start date: November 14, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).